Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPC-01
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LPC-01 is an investigational oral small molecule being developed by Otsuka Pharmaceutical for the treatment of hyperlipidemia. Currently in Phase 1 clinical development, the compound is being evaluated for its safety and tolerability, with a specific focus on its effects on the cardiac QT interval. This safety assessment is critical because LPC-01 is being compared to probucol, an older lipid-lowering medication known to cause QT prolongation. LPC-01 is administered twice daily and is intended to provide a new therapeutic option for managing lipid levels in patients with hyperlipidemia, potentially with an improved safety profile compared to existing agents in its class.
Beyond the preview
Go deeper on LPC-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPC-01.